- Record: found
- Abstract: found
- Article: not found
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson
1 ,
Graham W Slack ,
Kerry J Savage ,
Joseph M Connors ,
Susana Ben-Neriah ,
Sanja Rogic ,
David W Scott ,
King L Tan ,
Christian Steidl ,
Laurie H Sehn ,
Wing C Chan ,
Javeed Iqbal ,
Paul N Meyer ,
Georg Lenz ,
George Wright ,
Lisa M Rimsza ,
Carlo Valentino ,
Patrick Brunhoeber ,
Thomas M Grogan ,
Rita M Braziel ,
James R Cook ,
Raymond R Tubbs ,
Dennis D Weisenburger ,
Elias Campo ,
Andreas Rosenwald ,
German Ott ,
Jan Delabie ,
Christina Holcroft ,
Elaine S Jaffe ,
Louis M Staudt ,
Randy D Gascoyne
Oct 01 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis.